The cooperation of pharmacologic-dose ascorbate with ceftriaxone against Staphylococcus aureus through bactericidal synergy and enhanced macrophage killing activity

Chulamartd Wirapakorn,1 Uthaibhorn Singkham-in,1 Sujittra Taratummarat,1 Saowapha Surawut,1 Peerapat Visitchanakun,1 Tanittha Chatsuwan,2 Asada Leelahavanichkul2,3

Background: Ascorbate is a low-cost compound with a known bactericidal-synergy to antibiotics. However, the synergy depends on concentrations and organisms. Thus, the synergy test by time-kill assay might be appropriate for the screening of the synergy.

Objective: We aimed to test the adjuvant property of ascorbate with ceftriaxone, a frequently prescribed β-lactam antibiotic.

Method: Ascorbate was tested with several bacteria from the American Type Culture Collection (ATCC) including Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and Escherichia coli for i) bactericidal property of ascorbate, alone or with ceftriaxone-combination, by time-kill assay, ii) an influence on the killing-activity of bone-marrow-derived macrophage and iii) the attenuation of myositis mouse model.

Result: The bactericidal synergy (determined with time-kill assay at 24 h) against S. aureus, but not other selected bacteria, was demonstrated in ascorbate (10 and 40 mM) plus ceftriaxone at the minimal inhibitory concentration (1x MIC). Ascorbate alone, without antibiotic, enhanced macrophage killing-activity and directly eliminated bacteria at the concentration 10–40mM and 250mM, respectively (both properties presented against S. aureus and P. aeruginosa, but not other bacteria). Ascorbate with ceftriaxone also reduced bacterial burdens in muscle and serum cytokines of S. aureus-myositis mouse model. Moreover, the synergy against the clinical isolated methicillin resistant S. aureus (MRSA) by time-kill assay and myositis model also presented.

Conclusion: Ascorbate-ceftriaxone synergy against S. aureus was demonstrated by time-kill assay and myositis model. Time-kill assay might be valuable as a screening test to select the patients that potentially benefit from ascorbate-ceftriaxone adjuvant therapy.

Key words: Bactericidal synergy; Ascorbate; Pharmacologic dose; S. aureus; Ceftrixone
is well-known, the effectiveness of ascorbate-induced neutrophil bactericidal activity still depends on the organisms and ascorbate doses.

As such, ascorbate at very high concentrations (≥ 16–32 mM) is necessary for the demonstration of its bactericidal property. Likewise, the adjuvant effect of high doses of ascorbate against several diseases have been reported including Mycobacterium tuberculosis, Candida albicans, and malignancy. Interestingly, ascorbate in pharmacologic concentrations (between 10 and 40 mM) is easily achievable through its continuous intravenous administration in patients. Despite the reported cases of ascorbate-induced oxalosis, no renal complications were demonstrated in a clinical study in patients and in mice, possibly due to the short course of administration. Because the concentration of ascorbate with bactericidal activity might be reduced by the proper antibiotic combination, we tested ascorbate in the achievable concentrations that were demonstrated in the patients.

On the other hand, time-kill assay is the most appropriate method to determine the dynamic interaction between different antibiotics. This assay is frequently used to evaluate the synergism or antagonism of antibiotics in combination. The time-kill assay has been used to predict the effectiveness of combined antibiotics against resistant bacteria. As such, it is interesting to use the in vitro time-kill assay for the screening of ascorbate-antibiotic synergy in vivo. Moreover, the in vivo influence of ascorbate might be due to its immune modulating effect, because ascorbate is necessary for the activation of neutrophils. Hence, ascorbate possibly improves the function of macrophages because of the similar ROS-dependent killing activity between neutrophils and macrophages. Because the prevalence of Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherichia coli is high and the prescription of ceftriaxone, a broad spectrum β-lactam antibiotic, is common, we tested ascorbate-ceftriaxone synergy as a proof of concept experiment in vitro and in vivo.

Method

Bacteria preparation

Bacteria from the American Type Culture Collection (ATCC) including S. aureus (ATCC 25923), P. aeruginosa (ATCC 27853), A. baumannii (ATCC 19606), and E. coli (ATCC 25922) (ATCC, Manassas, VA, USA) were used. The minimal inhibitory concentrations (MICs) of ceftriaxone against these bacteria were 4, 16, 128, and 4 µg/mL, respectively. In addition, two clinically isolated strains of methicillin resistant S. aureus (MRSA) from patients in the intensive care unit were used to evaluate the possibility of the clinical translation. For MRSA identification, resistance to cefoxitin (30 µg) was demonstrated by the production of an inhibition zone ≤ 21 mm in disc susceptibility testing.

The time-kill assay

The time-kill assay was performed followed a previous study. Ascorbate (Sigma-Aldrich, St. Louis, MO, USA) at pH 7.35 in sterile water at different concentrations was used. Ascorbate at 10 and 40 mM concentrations were selected to test synergy, because these concentrations are achievable with continuous intravenous (iv) administration in patients. On the other hand, ascorbate concentrations more than 80 mM represent the hypothetical levels that might be associated with some in vivo complications. In the time-kill assay, each bacterial strain at 1 × 10^5 CFU/mL was incubated at 37°C with continuous shaking in several experimental groups including phosphate buffer solution (PBS) control, ascorbate, ceftriaxone (Sigma-Aldrich), and ceftriaxone plus ascorbate. In ceftriaxone alone and ceftriaxone plus ascorbate, ceftriaxone at 25% of the MIC (0.25x MIC) or at the MIC (1x MIC) against each bacterial strain was tested. Thus, different ceftriaxone concentrations were used for each bacterial strain due to the different MICs. Bacterial enumeration in colony forming units (CFUs) at 0, 2, 4, 6, 12, and 24 h of the assay were determined by 24 h incubation on tryptic soy agar (TSA; Oxoid, Hampshire, UK) at 37°C. The control of bacteria alone with neither ascorbate nor ceftriaxone was also performed. For MRSA, ceftriaxone at 512 µg/mL was used for the time-kill assay, because the MIC of ceftriaxone against both MRSA strains was higher than 512 µg/mL. Bacterial synergy was defined as the lower bacterial count at 24 h of the time-kill assay of ceftriaxone plus ascorbate (10 or 40 mM) in comparison with ceftriaxone alone. All experiments were done in triplicate.

Macrophage phagocytosis and killing activity

The effect of ascorbate on macrophage function was tested due to the limited data on the topic in contrast to the well-known influences of ascorbate on neutrophil function. The protocols of bone marrow (BM)-derived macrophage preparation and macrophage phagocytosis were followed. In brief, bacteria were killed by heat at 56°C for 60 min and adjusted into 1 × 10^5 cells/mL of PBS by the spectrophotometer (optical density at 600 nm; OD600nm). After that, bacteria were labeled with 500 µg of fluorescein isothiocyanate (FITC) (Sigma-Aldrich). Macrophages at 1 × 10^5 cells/well and heat-killed bacteria in the final ratios of macrophage to bacteria at 1:500 and 1:1000 in the final volume at 200 µL were co-cultured with ascorbate (10 or 40 mM). Then, 0.2% trypan blue in PBS was used to quench the non-phagocytosed FITC-negative bacteria (extracellular FITC-bacteria) and the intracellular fluorescent intensity was measured at the excitation and emission wavelengths of 493 nm and 520 nm. The intracellular fluorescent intensity represents the activity of macrophage phagocytosis. For macrophage killing activity, macrophages and live bacteria at the ratios of macrophage to bacteria at 1:100 with ascorbate (10 or 40 mM) was incubated at 37°C in a 5% CO2 incubator for 15 minutes and washed with PBS. And then gentamicin (Sigma-Aldrich) at 100 µg/mL in DMEM was mixed for extracellular bacteria eradication. After that, the culture supernatant was removed and cell lysis was induced with lysis medium (distilled water with 0.01% bovine serum albumin). Subsequently, cell lysates in the serial dilutions were plated on TSA (Oxoid) for 24 h before bacterial enumeration. Macrophage killing activity is inversely correlated with the number of bacterial colonies.
**Staphylococcal myositis mouse model**

Twelve-week-old male ICR mice purchased from the National Laboratory Animal Center, Nakornpathom, Thailand were used. The animal protocols were approved by the Faculty of Medicine at Chulalongkorn University following the National Institute of Health (NIH) criteria, USA. *S. aureus* ATCC 25923 or the clinical strains of MRSA at $3 \times 10^9$ CFU in 25 µL of normal saline (NSS) were intramuscularly administered into the left upper thigh of mice. Two hours later, four different experimental groups (n = 8/group) were conducted including 1) ceftriaxone alone; intraperitoneal (ip) ceftriaxone (10 mg/kg in NSS) with subcutaneous (sc) NSS injection, 2) ascorbate alone; ip NSS with sc ascorbate (0.5 g/kg/dose), 3) ceftriaxone plus ascorbate; ip ceftriaxone plus sc ascorbate in the previous doses, and 4) NSS alone; NSS ip and sc. The volume per dose of ip and sc injection was 50 µL and 125 µL, respectively. Then, ascorbate (0.5 g/kg/dose) or NSS at 125 µL was subcutaneously administered above the lesion every 2 h for three more injections. A subtherapeutic dose of ceftriaxone (10 mg/kg) was selected instead of the recommended dose (50 mg/kg) to determine synergy easier. Because of the rapid renal excretion of ascorbate after iv injection,14 the frequent sc injection of ascorbate was used to maintain ascorbate levels in the myositis mouse model.29

All mice were sacrificed with blood collection through cardiac puncture under isoflurane anesthesia 2 h after the last ascorbate injection (10 h after bacterial injection). Serum cytokines (TNF-α, IL-6, and IL-10) and serum ascorbate were analyzed by ELISA assays (eBioscience, San Diego, CA, USA) and ascorbic acid assays (BioAssay U.S. Biological, Salem, MA, USA), respectively. In addition, 100 mg of muscle at the inoculation site was homogenized in PBS then plated onto TSA (Oxoid) for bacterial colony enumeration as previously prescribed. The in vivo bactericidal synergy was defined as the lower bacterial burden in muscle at sacrifice in ceftriaxone plus ascorbate in comparison with ceftriaxone treatment alone.

**Statistical analysis**

Mean ± SE was used for data presentation and the differences between groups were determined by one-way analysis of variance (ANOVA) with Tukey’s comparison test. Repeated measures by ANOVA with Bonferroni post hoc analysis were used for the analysis of the data with several time-points. P values < 0.05 were considered statistically significant. SPSS 11.5 software (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.

**Results**

**Ascorbate bactericidal synergy by time-kill assay and macrophage killing activity**

Time-kill assay was performed to test the in vitro synergy. Ascorbate alone at 10 and 40 mM was not effective for bacterial neutralization (Figure 1). Ascorbate with ceftriaxone at 0.25x MIC reduced bacterial burdens at 3 through 12 h of incubation only in *P. aeruginosa*, but not other bacterial strains, in comparison with ceftriaxone alone (Figure 1 Left column).

---

**Figure 1.**
Asian Pac J Allergy Immunol DOI 10.12932/AP-171117-0200

macrophage killing activity against both \textit{S. aureus} and \textit{P. aeruginosa} were demonstrated only with ascorbate 40 mM, the killing activity against \textit{E. coli} with ascorbate 10 mM was better than with 40 mM (Figure 3).

Ascorbate bactericidal synergy against a staphylococcal myositis mouse model

A staphylococcal myositis mouse model was performed to test the \textit{in vivo} synergy. Because bacterial neutralization depends on ascorbate concentrations, serum ascorbate after sc injection was measured. As such, serum ascorbate between 10 and 40 mM was achievable within 1.5 h after a single sc injection, and ip ceftriaxone did not alter the ascorbate level (Figure 4A). Because the duration that ascorbate levels were more than 10 mM was only 1.5 h after a single sc injection, we then performed sc injection above the bacterial injection site every 2 h for a total of four doses. The mouse samples were collected 2 h after the last ascorbate injection. Ceftriaxone plus ascorbate showed the lowest bacterial burdens in muscle and serum cytokines (TNF-α, IL-6, and IL-10) (Figure 4B-4E). Because of the subtherapeutic dose of ceftriaxone, ceftriaxone treatment alone showed a tendency toward the reduction in bacterial burdens compared with non-antibiotic groups but did not reach statistically significant levels (Figure 4B). To more closely resemble the clinical situation, clinical isolates of MRSA were used. Ascorbate-ceftriaxone synergy was demonstrated with ascorbate at 10 mM and 40 mM in strain #1,
Ascorbate bactericidal synergy against S. aureus

Figure 2.

Figure 3.
Figure 4.

Figure 5.
Ascorbate bactericidal synergy against *S. aureus*

**Figure 5.** (Continued)

and synergy presented only with ascorbate 40 mM in strain #2, as determined by the time-kill assay at 24 h (*Figure 5A and 5B*). However, the *in vivo* bactericidal synergy as demonstrated by the lower bacterial burdens in muscle with ascorbate-ceftriaxone in comparison with ceftriaxone alone could be found only in MRSA strain #1 but not strain #2 (*Figure 5C-5F*).

**Discussion**

Ascorbate is low-cost, widely available, and the adjunctive administration of ascorbate with an antibiotic might be a beneficial strategy, especially in situations with limited resources. Thus, as a proof of concept experiment, we explored *in vitro* synergy with the time-kill assay and tested *in vivo* synergy with a myositis mouse model.

Although ascorbate is a potent anti-oxidant, ascorbate in the concentration > 0.2 mM shows pro-oxidant properties. After oral administration, ascorbate concentrations in blood are lower than 0.2 mM due to intestinal transporter saturation. The injection route is necessary to induce higher ascorbate blood levels, and bactericidal property was demonstrated at the level > 16 mM. However, the concentration might be lower with the appropriate antibiotic combination. While the bactericidal property of ascorbate was demonstrated with ascorbate alone between 80 mM and 250 mM in the time-kill assay, the bactericidal effect of ascorbate could be found between 10 mM and 40 mM in combination with an antibiotic. And ascorbate between 10 mM and 40 mM could be easily achievable in patients with the continuous iv injection without serious complications. However, an appropriate level of antibiotic is necessary as ascorbate-ceftriaxone synergy against *S. aureus* was demonstrated only with ceftriaxone at 1x MIC but not at 0.25x MIC. Moreover, the synergy was only working against the specific bacteria, as ascorbate-ceftriaxone reduced *P. aeruginosa* at 3 through 12 h after incubation but not at 24 h. This implied a possible ascorbate neutralization mechanism by *P. aeruginosa*. Hence, *in vitro* ascorbate-ceftriaxone synergy depends on i) concentrations of antibiotics and ascorbate and ii) the microorganisms. More studies are needed to explore the mechanisms of the synergy.

In addition, ascorbate-ceftriaxone synergy was also demonstrated *in vivo* with a staphylococcal myositis model. Hence, the *in vivo* synergy might be responsible for the synergistic bactericidal property together with the improved activity of immune cells. Likewise, the intracellular ascorbate concentration is 100-fold higher after macrophage activation and this might affect the killing activity. Another possible mechanism of *in vivo* ascorbate-antibiotic synergy is enhanced extracellular H$_2$O$_2$ production; however, this process might be neutralized during an acute infection. Finally, ascorbate-ceftriaxone synergy was tested against two clinical strains of MRSA as a proof of principle in antibiotic resistant strains of bacteria.

The synergy in the myositis model could be demonstrated only with strain #1, which the synergy was demonstrated with ascorbate at 10 mM and 40 mM by time-kill assay. In contrast, the synergy in the myositis model could not be demonstrated in strain #2, which the synergy was demonstrated only with ascorbate 40 mM by time-kill assay. Hence, the time-kill assay with ascorbate might be appropriate for the screening test of the clinical outcomes. However, only two strains of MRSA were tested in this study, and more intensive studies of MRSA will be necessary. Moreover, other methods to test synergy,
such as checkerboard analysis, might also be appropriate tests. More studies on the correlation of the in vitro analysis to the in vivo outcomes are in need.

Finally, several limitations should be mentioned. First, other antibiotics might be different from ceftriaxone for the demonstration of ascorbate bactericidal synergy. Second, the in vivo synergy against gram-negative bacteria was not tested, because a gram-negative bacterial challenge could not produce myositis (data not shown). Third, the synergy demonstrated here depends on local activity and not systemic administration.

In conclusion, a proof of concept study to use ascorbate as an adjunctive therapy to antibiotics against bacterial infection was demonstrated. This synergy might be beneficial in situations with limited resources. In the real clinical situation, ascorbate monitoring in serum and antibiotic concentrations might improve the efficacy of synergy. With more intensive studies, ascorbate-antibiotic synergy might be an alternative choice against antibiotic resistant bacteria, but more studies are warranted.

Acknowledgments
AL worked under the Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine. This study was supported by Thailand Government Fund (RSA-6080023)

References